Block Linda, Lundborg Christopher, Bjersing Jan, Dahm Peter, Hansson Elisabeth, Biber Björn
*Department of Anesthesiology and Intensive Care Medicine †Department of Rheumatology, Institute of Clinical Sciences ‡Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Clin J Pain. 2015 Nov;31(11):968-75. doi: 10.1097/AJP.0000000000000200.
This randomized, cross-over, double-blind, controlled study of continuous intrathecal morphine administration in patients with severe, long-term pain addresses whether the supplementation of low doses of naloxone in this setting is associated with beneficial clinical effects.
All of the study subjects (n=11) provided informed consent and were recruited from a subset of patients who were already undergoing long-term treatment with continuous intrathecal morphine because of difficult-to-treat pain. The patients were (in a randomized order) also given intrathecal naloxone (40 ng/24 h or 400 ng/24 h). As control, the patients' ordinary dose of morphine without any additions was used. The pain (Numeric Rating Scale, NRS) during activity, perceived quality of sleep, level of activity, and quality of life as well as the levels of several proinflammatory and anti-inflammatory cytokines in the blood were assessed. The prestudy pain (NRS during activity) in the study group ranged from 3 to 10.
A total of 64% of the subjects reported improved quality of sleep during treatment with naloxone at a dose of 40 ng per 24 hours as compared with 9% with sham treatment (P=0.024). Although not statistically significant, pain was reduced by 2 NRS steps or more during supplemental treatment with naloxone in 36% of subjects when using the 40 ng per 24 hours dose and in 18% of the subjects when using naloxone 400 ng per 24 hours dose. The corresponding percentage among patients receiving unaltered treatment was 27%.
To conclude, the addition of an ultralow dose of intrathecal naloxone (40 ng/24 h) to intrathecal morphine infusion in patients with severe, persistent pain improved perceived quality of sleep. We were not able to show any statistically significant effects of naloxone on pain relief, level of activity, or quality of life.
本项针对患有严重长期疼痛患者的连续鞘内注射吗啡的随机、交叉、双盲对照研究,探讨在此情况下补充低剂量纳洛酮是否具有有益的临床效果。
所有研究对象(n = 11)均提供了知情同意书,他们是从因疼痛难以治疗而已经在接受连续鞘内注射吗啡长期治疗的患者亚组中招募的。患者还(按随机顺序)接受鞘内注射纳洛酮(40纳克/24小时或400纳克/24小时)。作为对照,使用患者未添加任何物质的普通吗啡剂量。评估了活动期间的疼痛(数字评分量表,NRS)、睡眠感知质量、活动水平、生活质量以及血液中几种促炎和抗炎细胞因子的水平。研究组的研究前疼痛(活动期间的NRS)范围为3至10。
与假治疗组的9%相比,总共64%的受试者报告在接受每24小时40纳克剂量纳洛酮治疗期间睡眠质量得到改善(P = 0.024)。虽然无统计学意义,但在使用每24小时40纳克剂量纳洛酮补充治疗期间,36%的受试者疼痛减轻了2个NRS等级或更多,使用每24小时400纳克剂量纳洛酮时,18%的受试者疼痛减轻。接受未改变治疗的患者中相应的百分比为27%。
总之,在患有严重持续性疼痛的患者中,鞘内注射吗啡时添加超低剂量的鞘内纳洛酮(40纳克/24小时)可改善睡眠感知质量。我们未能显示纳洛酮对疼痛缓解、活动水平或生活质量有任何统计学上的显著影响。